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cheap. Whether initial treatment should be extended to long-term regimes is a
point of contention beyond the scope of the present article.
An extremely important point emphasised by the authors is the definition of
treatment failure, particularly with reference to injection sclerotherapy. They have
clearly shown that repeated attempts to manage bleeding by sclerotherapy are
associated with diminishing returns and it is suggested that 2 attempts at endoscopic
treatment is all that is justified before recourse to other measures. The results of
stapling transection observed in the present trial would strongly support this
technique for the early rescue of patients who have failed endoscopic therapy. Any
such intervention should be considered over a period of hours rather than days
after the time of presentation. The only reservation with respect to this advice may
be the possible adverse effect of staple transection upon any subsequently planned
liver transplantation.
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TWO VARIETIES OF INTRAHEPATIC
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Background. To find the rational surgical strategy for the treatment of intrahepatic
cholangiocarcinoma (ICC), clinical features of ICC were studied in 20 patients who
underwent hepatic resection in the National Cancer Center Hospital from 1980 to
1990.
Methods. According to the morphologic pattern, we classified the ICCs into two
subcategories, mass-forming and infiltrating, which correlated with their biologic
behavior.
Results. Of 10 patients who underwent hepatectomy for mass-forming ICC, three
survived more than 5 years without recurrence. The 1-, 3-, and 5-year survival rates
were 59.3%, 44.4%, and 44.4%, respectively. Of 10 patients who underwent
hepatectomy for infiltrating ICC, one survived more than 5 years without recur-
rence. The 1-, 3-, and 5-year survival rates were 72.0%, 27.0%, and 27.0%,
respectively. The pathologic findings and recurrences indicated that the salient
feature of the mass-forming type was its tendency for intrahepatic metastasis
especially near a main lesion, and of the infiltrating type was the infiltrative spread
via Giisson’s capsule and hilar lymph nodal metastasis.
Conclusions. An anatomic and extensive liver resection should be performed for
mass-forming ICC, whereas a hepatectomy with excision of the extrahepatic bile
duct and hilar lymph nodal dissection is recommended for infiltrating ICC. (Surgery
1992; 111: 617-22)
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Over the last decade the clinicopathology of intrahepatic cholangiocarcinoma
(ICC) has been elucidated more clearly. ICC, the second most frequent histotype
of primary hepatic malignancy, has proven itself formidable. Yamamoto and
colleagues have emphasized this fact in their detailed report of only four patients
with ICC surviving five years or more after resection. Their message is both
encouraging and sobering.
ICC or peripheral cholangiocarcinoma accounts for 10-20% of primary hepatic
malignancies’. In contrast to hepatocellular carcinoma, concurrent chronic liver
disease exists less frequently3. The clinical presentation of ICC is not pathognomo-
nic. Gross morphology of ICC is similar to that of hepatocellular carcinoma and is
equally divided between massive and infiltrating types. Although Yamamoto et al.
reported only their experience with patients who underwent resection, other
investigators have shown infrequent resectability because of the advanced diseases-
tage at diagnosis-4. Similar detailed pathologic studies of ICC have shown that
intrahepatic tumor spread and regional lymph node and distant organ metastases
occur in nearly 70% and 85% of patients respectively4’5. Yamamoto et al. also
found that intrahepatic vascular invasion, intrahepatic metastases, bile duct
invasion and lymph node metastases occurred in nearly 50% of their patients.
These pathologic findings affirm the acknowledged aggressive biologic behavior of
ICC. Not surprisingly resectability is infrequent. Even when ICC is resectable,
lobar or extended lobar resections are generally required to encompass all grossHPB INTERNATIONAL 331
disease. Despite extensive hepatic resections reported by Yamamoto et al. herein
and others,
2-4 five-year disease-free survival is rare. The only inexplicable excep-
tion to all other reports is that by Iwatsuki and Starzl
6 who found that ICC was not
associated with a poor prognosis, though actual five-year survival was estimated.
No report to date has addressed the relationship ofTNM stage and survival for this
histotype.
What is the clinical impact of the report on ICC by Yamamoto et al. ? First, their
report establishes that surgical therapy has a potentially curative role for this
primary hepatic malignancy, albeit infrequently. Clearly surgical therapy should
not be abandoned based on the histology of preoperative tumor biopsy alone.
Moreover, careful staging evaluation is required to define resectability because of
the high risk of metastatic disease with this histotype. Secondly, subsequent reports
of the outcome of surgically treated patients with ICC are warranted to determine
factors predictive of both resectability and survival in patients with ICC. Reports
on ICC are few. Indeed, surgeons are just beginning to learn of this tumor.
Additional information regarding staging, resectability rates, and outcomes will aid
in the development of future treatment strategies for patients with ICC. Finally, as
with other malignancies associated with a poor prognosis and requiring major
procedures with significant operative risk, surgeons need to critically define the
selection criteria for those patients likely to benefit from resection. Fully 50% of
the patients reported by Yamamoto et al. survived one year or less. One wonders
whether resection had any impact on disease progression in these patients. Clinical
performance status of patients and assessment of the quality of life both before and
after surgery must be addressed in the future to justify the effort required in the
management of patients with ICC.
In summary, Yamamoto et al. have called further attention to the challenge of
ICC. Although they have provided a glimmer of hope for both patients and
surgeons alike by documenting five year survival in four patients, they have fully
recognized limitations in resection alone. Perhaps the stimulus of this report will
spurn others to critically review their experiences and uncover other salient
features of ICC which will lead to improved outcome from surgical management.
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